Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Research Efforts Examining Novel Radiation Approaches Flourish at Fox Chase Cancer Center

May 21st 2021

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

Novel Combinations Being Investigated for mCRC Treatment

May 21st 2021

Current trials exploring novel combinations that show potential in making microsatellite stable tumors hot and amenable to response to immunotherapy in metastatic colon cancer.

Dual I-O Therapy for mCRC

May 21st 2021

Drs Cathy Eng and Joleen M. Hubbard discuss the rationale for studying dual immunotherapy approaches for metastatic colorectal cancer treatment.

Dr. Eng on the Rationale for Studying the Impact of RAS Mutations in Early Onset Resectable CRC

May 21st 2021

Cathy Eng, MD, FACP, FASCO, discusses the rationale for studying the impact of RAS mutations in patients with early onset resectable colorectal cancer.

Dr. Eng on Surgical Considerations for RAS-Mutant CRC

May 19th 2021

Cathy Eng, MD, FACP, FASCO, discusses surgical considerations for patients with RAS-mutant colorectal cancer.

Dr. Hubbard on Utilizing Single-Agent Immunotherapy in MSI-H CRC

May 18th 2021

Joleen M. Hubbard, MD, discusses the potential for treatment with immunotherapy alone in patients with colorectal cancer.

Pan-cancer Multigene Panel Testing Should Be a Standard Screening Measure in CRC

May 18th 2021

The use of universal tumor screening in conjunction with multigene panel testing led to an improvement in the identification of hereditary cancer syndromes in patients with colorectal cancer.

Dr. Eng on the Impact of RAS Mutations on Outcomes in Early vs Late CRC Following Liver Resection

May 17th 2021

Cathy Eng, MD, FACP, FASCO, discusses the impact of RAS mutations on outcomes in patients with early vs late colorectal cancer following liver resection.

Dr. Coveler on Replacing 5-FU With NUC-3373 in mCRC

May 14th 2021

Andrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.

Dr. Grothey on the Potential Role of ctDNA as a Marker for Rechallenging Treatment in CRC

May 14th 2021

Axel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.

Best Practices Surrounding IO Treatment for mCRC

May 14th 2021

Kanwal Raghav, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses when it is most appropriate to initiate immunotherapy for metastatic colorectal cancer, highlighting the roles of tumor mutation burden and microsatellite instability as biomarkers for treatment.

Frontline I-O Treatment for mCRC

May 14th 2021

Cathy Eng, MD, FACP, FASCO, describes data revealed by the KEYNOTE-177 trial and discusses best practices for using immunotherapy as first-line treatment of metastatic colorectal cancer.

Universal Genetic Testing Reveals Variants Linked With Increased Cancer Risk in CRC

May 13th 2021

One in 6 patients with colorectal cancer harbor genetic changes that substantially increase their risk for cancer, especially in those who are younger at the time of diagnosis.

3-Month Adjuvant CAPOX Represents Potential Option for Select High-Risk Stage II CRC

May 13th 2021

Three months of adjuvant capecitabine plus oxaliplatin represents a potential option for select patients with high-risk stage II colorectal cancer due to its convenience, reduced toxicity, and cost, although noninferiority to the 6-month standard duration was not demonstrated.

Dr. Messersmith on the Potential for Trastuzumab Deruxtecan in HER2+ CRC

May 12th 2021

Wells Messersmith, MD, discusses the potential for fam-trastuzumab deruxtecan-nxki as a treatment for patients with HER2-positive colorectal cancer.

Dr. Raghav on Adjusting Dosing With Regorafenib in CRC

May 11th 2021

Kanwal Raghav, MBBS, MD, discusses adjusting dosing with regorafenib in patients with colorectal cancer.

Dr. Raghav on Selecting Between TAS-102 and Regorafenib in CRC

May 10th 2021

Kanwal Raghav, MBBS, MD, discusses the process of selecting between treatment with trifluridine and tipiracil vs regorafenib in patients with colorectal cancer.

Biomarker Testing and Precision Medicine in mCRC

May 7th 2021

A panel of gastrointestinal oncologists discuss current options for molecular testing based on the understanding that predictive biomarkers play a role in the management of metastatic colon cancer.

Fruquintinib for Refractory mCRC

May 7th 2021

Expectations regarding the use of fruquintinib, an oral VEGF tyrosine kinase inhibitor, as third-line therapy for metastatic colorectal cancer.

Dr. Marshall on Early Data With Trastuzumab Deruxtecan in HER2+ CRC

May 6th 2021

John L. Marshall, MD, discusses early data reported with fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive colorectal cancer from the phase 2 DESTINY-CRC01 trial.